PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

Chart, page-1410

  1. 160 Posts.
    lightbulb Created with Sketch. 182
    Honestly, I've dropped the ball on this one since I've just got profit sitting in here now but the chart is looking better and starting the MPS-1 trial is a good sign.

    Perhaps someone here may know the answer but I remember that Paradigm was given orphan designation for MPS-1,

    does this mean that a phase 3 trial will be required?

    Also, will Phase 1 and 2 trials still be required for other types of MPS such as MPS 3 or 4?

    Thanks!
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.